Clinical Trial Update: Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab in combination with lenvatinib for high-risk locally advanced cervical cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Adenocarcinoma
• Cervical Cancer
• Cervical Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Prof. Dr. Remi A. Nout | Conditions: Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2 | Phase 2 | Status: NOT_YET_RECRUITING